Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders

Research output: Contribution to journalReview article

372 Scopus citations

Abstract

Epigenetic chromatin remodeling and modifications of DNA represent central mechanisms for regulation of gene expression during brain development and in memory formation. Emerging evidence implicates epigenetic modifications in disorders of synaptic plasticity and cognition. This review focuses on recent findings that HDAC inhibitors can ameliorate deficits in synaptic plasticity, cognition, and stress-related behaviors in a wide range of neurologic and psychiatric disorders including Huntington's disease, Parkinson's disease, anxiety and mood disorders, Rubinstein-Taybi syndrome, and Rett syndrome. These agents may prove useful in the clinic for the treatment of the cognitive impairments that are central elements of many neurodevelopmental, neurological, and psychiatric disorders.

Original languageEnglish (US)
Pages (from-to)57-64
Number of pages8
JournalCurrent Opinion in Pharmacology
Volume8
Issue number1
DOIs
StatePublished - Feb 1 2008

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders'. Together they form a unique fingerprint.

  • Cite this